Ainos

Ainos EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Ainos (AIMD) as of Oct 16, 2026 is -67.36 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -49.43 % — a change of 36.27% (lower).

EBIT/Assets

-67.36 %

YoY

36.27%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Ainos is 2025 -67.36 % . Operating Income to Assets Ratio (EBIT/Assets) of Ainos was 2024 -49.43 % . It decreases by 36.27% lower compared to the previous year.

The Ainos EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-91.19 USD
Jan 1, 2019
-264.89 USD
Jan 1, 2020
-553.40 USD
Jan 1, 2021
-9.48 USD
Jan 1, 2022
-37.60 USD
Jan 1, 2023
-42.92 USD
Jan 1, 2024
-49.43 USD
Jan 1, 2025
-67.36 USD
The Ainos EBIT/Assets history
YEAREBIT/AssetsYoY
-67.36 %+36.27%
-49.43 %+15.16%
-42.92 %+14.16%
-37.60 %+296.63%
-9.48 %-98.29%
-553.40 %+108.91%
-264.89 %+190.50%
-91.19 %+260.77%
-25.27 %-82.47%
-144.19 %-67.49%
-443.55 %+200.31%
-147.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ainos Stock analysis

What does Ainos do? Ainos Inc, a U.S.-based biotechnology company headquartered in San Diego, California, operates in the health care sector. The company, which went public on August 8, 1996, currently employs 43 full-time staff. Ainos Inc focuses on developing medical technologies for point-of-care testing and medical treatments across various disease indications. The company's research and development activities include securing intellectual property and commercializing therapeutics, particularly those utilizing low-dose non-injectable interferon (IFN). Among its product offerings are the COVID-19 Antigen Rapid Test Kit, VOC POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, VELDONA (Very Low-Dose Oral Interferon Alpha), and Synthetic RNA (SRNA). The VOC POCT-Ainos Flora device is designed for non-invasive testing related to female vaginal health and certain sexually transmitted diseases. The VOC POCT-Ainos Pen is a portable, cloud-connected breath analyzer intended for health monitoring. The VOC POCT-CHS430 device aims to provide non-invasive testing for ventilator-associated pneumonia. Ainos Inc's website is www.ainos.com. The company's operational focus remains on advancing medical technologies for point-of-care applications. Ainos is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ainos stock

Operating Income to Assets Ratio (EBIT/Assets) of Ainos is -67.36 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Ainos changed from -49.43 % to -67.36 %, representing a 36.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Ainos since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Ainos with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Ainos

All Key Metrics — Ainos